Ways to Boost the Aging Immune System

Boosting the Aging Immune System: An Evidence-Graded Review of Interventions for Older Adults

By Caluda AI - Aug 2026

TL;DR - The highest-value, best-proven interventions for an 80-year-old are the age-specific vaccines (recombinant zoster/Shingrix — 89.8% efficacy against herpes zoster in adults ≥70y [Cunningham ZOE-70, NEJM 2016]; high-dose/adjuvanted influenza; RSV; pneumococcal) plus regular exercise, adequate protein, sleep, and correcting true nutrient deficiencies (vitamin D, zinc, selenium) — not high-dose supplementation of already-replete people. - Nearly every micronutrient (vitamin D, zinc, vitamin C, selenium, vitamin A) shows benefit mainly in deficient/insufficient individuals; the big RCTs — VITAL [CID 2024] and D-Health [Lancet D&E 2022] — were NULL for infection and mortality in largely replete older populations. - The "anti-immunosenescence" pharmacology (TRIIM thymic regeneration, GlyNAC, spermidine, mTOR inhibitors, metformin) is mechanistically exciting but ranges from Moderate (spermidine pilot, GlyNAC) to Weak/Speculative (TRIIM n=9; RTB101 failed its phase 3 primary endpoint [PROTECTOR-1]); none is ready as a proven clinical recommendation.

Highest-Value Actions First (ranked by evidence strength × effect size)

  1. Get the age-specific vaccines. Shingrix (STRONG, 89.8% efficacy against zoster in ≥70y, holding at ~90% even at ≥80y), high-dose/adjuvanted influenza annually, RSV vaccine, pneumococcal, and current COVID boosters. This is the single most evidence-backed way to "improve immunity" against the diseases that actually threaten an 80-year-old.
  2. Exercise regularly (resistance + moderate aerobic) — robust anti-inflammatory and vaccine-adjuvant effects.
  3. Maintain adequate protein (1.0–1.2 g/kg/day) and avoid sarcopenia/frailty.
  4. Correct true deficiencies of vitamin D (target ~30–50 ng/mL with daily 800–2000 IU, not bolus),
    zinc (15–30 mg/day), and
    selenium if low. Repletion — not megadosing — is the operative principle.
  5. Protect sleep (7–8 h), especially around vaccination; reduce chronic stress/loneliness.
  6. Reduce excess adiposity (while preserving muscle), moderate alcohol, and stop smoking.
  7. Probiotics/fermented foods for modest reduction in respiratory infection incidence/duration.
  8. Oral hygiene and deprescribing unnecessary PPIs/steroids.

Key Findings

Immunosenescence (thymic involution, naïve T-cell depletion, B-cell repertoire contraction) and inflammaging (chronic low-grade IL-6/TNF/CRP elevation) drive the older adult's excess risk of respiratory infection, poor vaccine response, herpes zoster, and cancer. The interventions below are graded by strength of evidence specifically in older adults.

The single most important conceptual point for this reader: for the classic micronutrients, benefit is a repletion phenomenon. Deficient people benefit; replete people generally do not, and in some cases (vitamin A, possibly high-dose vitamin D bolus) supplementation of the replete may be neutral or harmful. Indeed, in the individual-patient-data meta-analysis, vitamin D reduced acute respiratory infection "in individuals receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI 0.72–0.91), but not in those receiving one or more bolus doses (aOR 0.97, 95% CI 0.86–1.10)" [Martineau BMJ 2017].

Details — Comparison Table

Intervention Proposed immune benefit / mechanism Strength of evidence (graded) Conditions/outcomes with evidence Typical dose for seniors Cautions
Recombinant zoster vaccine (Shingrix/RZV) gE + AS01B adjuvant overcomes immunosenescence, drives cell-mediated + humoral immunity STRONG (two pivotal RCTs, >30,000, ZOE-50/70; 11-yr follow-up) Herpes zoster: VE 97.2% (≥50y, ZOE-50); 89.8% (95% CI 84.2–93.7) in ≥70y — 90.0% at 70–79y and 89.1% at ≥80y. Pooled ZOE-50/70: HZ 91.3% (95% CI 86.8–94.5), postherpetic neuralgia 88.8% (95% CI 68.7–97.1). Durability: 79.8% (95% CI 73.7–84.6) over years 6–11 (ZOE-LTFU) 2 doses IM, 2 months apart Marked reactogenicity (pain, myalgia); no live-virus risk
High-dose / adjuvanted influenza vaccine 4× hemagglutinin (HD) or MF59 adjuvant boosts blunted antibody response STRONG for relative benefit vs standard dose; MIXED on absolute hospitalization Lab-confirmed influenza: rVE 24.2% (95% CI 9.7–36.5) vs SD in the pivotal RCT (DiazGranados, NEJM 2014); meta-analysis rVE ~10–14% for ILI/hospitalization. BUT DANFLU-2 (n=332,438, NEJM 2025) found HD "did not result in a significantly lower incidence of hospitalization for influenza or pneumonia" (0.68% vs 0.73%) Annual; HD-IIV or aIIV preferentially for ≥65y More injection-site/systemic reactions; egg allergy considerations
RSV vaccine (older adults) Prefusion F antigen, some adjuvanted, restores protective response STRONG (phase 3 RCTs in ≥60y) RSV lower respiratory tract disease; neutralizing titers and CD4 response boosted Single dose; per current ACIP guidance for ≥75y and 60–74y at risk Reactogenicity; rare GBS signal under surveillance
Pneumococcal / COVID vaccines Serotype-specific IgG/OPA; direct protection against pneumococcal + SARS-CoV-2 disease STRONG (established programs) Invasive pneumococcal disease, pneumonia; COVID hospitalization/death PCV20 or PCV15+PPSV23; COVID boosters per schedule Generally well tolerated
Exercise (resistance, aerobic, moderate) Myokine (IL-6) release, restores Th1/Th2 balance, lowers CRP/TNF, improves vaccine response MODERATE–STRONG (multiple RCTs/meta-analyses in ≥60y) Lower CRP/TNF; improved influenza/COVID vaccine seroconversion (H1 seroconversion aOR 1.69, 95% CI 1.02–2.82; titer aOR 1.20, 95% CI 1.03–1.39); reduced infection susceptibility ≥150 min/wk moderate aerobic + 2×/wk resistance; acute bout near vaccination may help Avoid overtraining; individualize for frailty/cardiac status
Adequate protein / sarcopenia prevention Substrate for immunoglobulins, acute-phase proteins, lymphocyte proliferation; muscle as immune-metabolic reserve MODERATE (consensus guidelines; mechanistic + observational) Preserved immune competence, reduced infection/frailty, better recovery 1.0–1.2 g/kg/day (PROT-AGE); 1.2–1.5 g/kg/day in acute illness Adjust in advanced CKD; distribute across meals
Vitamin D Induces cathelicidin/LL-37, β-defensin; modulates T-cell response; VDR in immune cells MODERATE, with important NULLs — benefit largely confined to deficient ARI overall OR 0.92 (95% CI 0.86–0.99), 2021 meta-analysis; benefit only with daily/weekly (aOR 0.81) not bolus dosing (aOR 0.97). VITAL (mean 25(OH)D 31 ng/mL) & D-Health NULL for URI and all-cause mortality in replete elderly 800–2000 IU/day (daily, not bolus); target 25(OH)D ~30–50 ng/mL; repletion if <20 ng/mL Monthly bolus (D-Health) raised cancer-death point estimate; avoid hypercalcemia; UL 4000 IU/day
VDR activators (resveratrol, curcumin, omega-3, quercetin, sulforaphane, butyrate, berberine) Directly/indirectly bind or upregulate VDR; potentiate 1,25D signaling, antimicrobial peptide gene expression SPECULATIVE for clinical immunity (mechanistic/in-vitro; no infection RCTs via VDR) In-vitro VDR transactivation (resveratrol potentiates 1,25D binding; quercetin/curcumin direct ligands; sulforaphane/curcumin ↑VDR expression); no clinical infection endpoints proven through this mechanism No established "VDR-activation" dose; omega-3 ~1–2 g/day has independent evidence Curcumin/quercetin bioavailability poor; CYP interactions; do not substitute for vitamin D itself
Zinc Required for thymulin, T-cell development, NK function; corrects age-related deficiency MODERATE (RCTs incl. Prasad 2007; Cochrane on colds); benefit greatest in deficient Reduced incidence of infections in elderly (Prasad: 45 mg/day×12mo); shorter cold duration (acetate >75 mg/day); pneumonia risk with low serum zinc (nursing-home residents with low zinc had ~2× pneumonia) 15–30 mg/day elemental for repletion; higher acute doses for colds studied >40 mg/day chronically → copper deficiency; ZENITH showed replete elderly gain little
Vitamin C Antioxidant; supports neutrophil/phagocyte function, epithelial barrier MODERATE for severity/duration; WEAK for prevention in general population Cold duration ↓8% adults (regular use, Cochrane 2013); severity ↓15% (95% CI 9–21%); prevention only in physically stressed (RR 0.48, 95% CI 0.35–0.64); pneumonia risk ↓ in low-intake groups ≥0.2 g/day (prevention studied); 1–2 g/day for duration/severity GI upset, oxalate/renal stones at high dose; benefit mainly at low baseline
Selenium Selenoproteins (glutathione peroxidase); restores lymphocyte proliferation, NK activity WEAK–MODERATE; benefit in deficient (much of Europe is low) Improved lymphocyte/NK function in deficient elderly; KiSel-10 (Se 200 mcg + CoQ10) reduced CV mortality; COVID mortality associated with deficiency 100–200 mcg/day (selenium yeast in trials) Narrow window; >400 mcg/day → selenosis; possible ↑diabetes risk with excess
Vitamin A Maintains mucosal/epithelial barriers, retinoid-dependent T-cell responses STRONG in deficient children; NULL/possible HARM in replete ↓All-cause mortality, diarrhea, measles in deficient children; Cochrane 2024 (CD015306): "may be no benefit" for URI prevention; excess may ↑respiratory infection in the replete (Grotto meta-analysis) RDA 700–900 mcg RAE; supplement only if deficient Preformed vitamin A hepatotoxic/teratogenic; harm signal in replete; avoid routine supplementation
Sleep quality/duration Consolidates immunological memory; regulates Th1/Th2, cytokines; supports vaccine response MODERATE (experimental + observational; meta-analysis) <6 h/night around vaccination → blunted antibody response (Current Biology meta-analysis); acute deprivation reduces early titers (esp. males); poor sleep ↑infection risk 7–8 h/night; protect sleep in nights surrounding vaccination; consider morning vaccination Screen for apnea; caution with sedative-hypnotics in elderly
Stress reduction / social connection Lowers chronic cortisol/catecholamine immunosuppression; loneliness drives inflammaging WEAK–MODERATE (observational; some mindfulness RCTs) Chronic stress/loneliness → impaired vaccine response, higher inflammation; mindfulness modestly lowers inflammatory markers Mindfulness, social engagement, MBSR programs Low risk; adjunctive
Weight loss / reducing adiposity Reduces leptin/insulin dysregulation and adipose inflammation impairing T-cell & vaccine response MODERATE (mechanistic + epidemiological) Obesity → 2× influenza/ILI despite antibodies; faster waning of COVID neutralizing antibodies; more severe infection Gradual loss preserving muscle; combine with resistance training + protein In the very old, unintentional weight loss/frailty is more dangerous than mild overweight
Probiotics / fermented foods Modulate gut-immune axis, SCFA production, mucosal immunity MODERATE (Cochrane + meta-analyses) Upper respiratory infection: fewer episodes (RR 0.77, 95% CI 0.68–0.87), shorter duration; probiotic fermented dairy ↓RTI in elderly (RR 0.78, 95% CI 0.61–0.98) Multi-strain Lactobacillus/Bifidobacterium; daily Caution in severely immunocompromised (rare bacteremia)
Omega-3 fatty acids Specialized pro-resolving mediators; resolve inflammation; VDR/PPAR ligand WEAK–MODERATE for immunity (VITAL omega-3 arm null for infection) Lower inflammatory markers; mixed infection data; possible autoimmune-incidence reduction (VITAL exploratory) 1–2 g/day EPA/DHA Bleeding risk at high dose; AF signal in some trials
Spermidine Induces autophagy via eIF5A/TFEB; restores B/T memory function MODERATE-but-preliminary (one RCT pilot n=40, ≥65y) After COVID booster: overall anti-spike IgG increase was NOT statistically significant; enhanced spike-specific IgG, memory B-cell recall and neutralizing activity seen specifically in "non-responders" (8 of 20 with low baseline IgG); ↓lymphocyte p16 senescence; enhanced B-cell autophagy 6 mg/day ×13 weeks (trial dose); dietary sources wheat germ, mushrooms Small pilot only; higher doses untested; generally regarded safe
GlyNAC (glycine + NAC) Restores glutathione synthesis; lowers oxidative stress & inflammation MODERATE-but-small (RCTs by one group, n≈24 older adults) ↓Inflammation (TNF, CRP), corrected GSH deficiency, improved strength/gait/cognition; immune endpoints indirect Glycine + NAC dosed to ~100 mg/kg each (trials); 16–24 weeks Single-group replication; GI effects; needs independent confirmation
Liposomal glutathione / NAC alone Antioxidant; NAC alone did not raise RBC-GSH or lower inflammation in trials WEAK (NAC-alone negative; liposomal GSH little RCT data) NAC alone failed to improve GSH/oxidative stress/TNF in human trials; the combination (GlyNAC) is needed Variable Prefer GlyNAC over NAC alone; limited data on liposomal form
Thymic regeneration (TRIIM/TRIIM-X: rhGH + DHEA + metformin) Regrow thymus, restore naïve T-cell output, reverse epigenetic age SPECULATIVE (TRIIM n=9, uncontrolled pilot; TRIIM-X ongoing, ages 40–80) MRI thymic fat→tissue conversion, modest ↑naïve CD4/CD8, ↓epigenetic age (~2.5 yr); no infection outcomes Personalized rhGH + DHEA 50 mg + metformin; + D3 3000 IU + zinc 50 mg (trial co-supplements) rhGH promotes insulin resistance/edema/possible cancer risk; not a validated therapy
mTOR inhibitors (RTB101, everolimus — Mannick trials) Low-dose TORC1 inhibition augments type-I interferon antiviral response, improves vaccine response MODERATE→NEGATIVE (positive phase 2a/2b; phase 3 PROTECTOR-1 FAILED primary endpoint) Phase 2b: ↓lab-confirmed RTI (OR 0.601, 90% CI 0.391–0.922). Phase 3 (n=1,024): CSRI 0.46 (RTB101) vs 0.44 (placebo), OR 1.07, p=0.65 — no benefit; consistent IFN-gene upregulation across trials RTB101 10 mg/day (trial); not marketed Program terminated; higher mTOR doses immunosuppressive
Metformin TORC1 modulation, autophagy, ↓inflammaging; putative geroprotector WEAK for causation (observational only; TAME designed but unfunded/unreported) In diabetics: lower pneumonia mortality (matched RR 0.86 at 30d, 0.85 at 90d in VA elderly); lower influenza complications (pneumonia HR 0.63, 95% CI 0.53–0.76); lower COVID mortality (OR ~0.64–0.66) — all confounded/observational TAME design: 1500 mg/day, ages 65–79, n=3,000 (PI Barzilai) B12 deficiency, GI effects, may blunt exercise adaptations; no RCT proof for non-diabetics
Rapamycin / everolimus (geroscience use) Direct mTOR inhibition; enhanced vaccine response in elderly (RAD001 study) WEAK/SPECULATIVE for infection prevention (off-label; no positive phase 3) Everolimus improved influenza vaccine response in ≥65y (Mannick 2014); RTB101 phase 3 negative Intermittent low-dose regimens studied; no approved geroscience protocol Immunosuppression, mouth ulcers, dyslipidemia, glucose intolerance
Beta-glucans / medicinal mushrooms / colostrum-lactoferrin Trained innate immunity; dectin-1 signaling; mucosal defense WEAK (small/heterogeneous trials) Some ↓URI incidence/symptoms in small trials; no strong elderly-specific RCTs Variable Quality/standardization varies
Elderberry (Sambucus nigra) Anthocyanins, antiviral/anti-inflammatory WEAK (positive meta-analysis n=180; best independent RCT negative) Hawkins 2019 meta-analysis (4 RCTs, 180 subjects) suggested reduced URI symptoms, but Macknin 2020 RCT (n=87, lab-confirmed influenza) found NO benefit; JGIM editorial advised against use Syrup/extract, product-dependent Small/industry-linked positive trials; not recommended based on best RCT
Echinacea Immunomodulation of innate response WEAK/MIXED (Cochrane: no significant benefit) Cochrane 2014 (24 trials, 4,631): no significant prevention; at most 10–20% RRR of "unclear clinical relevance"; treatment not proven. Positive meta-analyses (Shah 2007 OR 0.42; ERA-PRIMA 2024) pooled heterogeneous/industry-linked products Product-dependent; no standard Heterogeneous products; independence concerns in positive reviews
Oral/dental health Reduces oral pathogen burden and systemic inflammation; aspiration pneumonia prevention MODERATE (RCTs of oral care in nursing homes) Oral hygiene programs reduce aspiration pneumonia in institutionalized elderly Daily oral care, dental review Low risk
Smoking cessation / alcohol moderation Removes direct immunosuppressants and barrier/ciliary damage STRONG (epidemiological) Smoking ↑pneumonia, influenza, COVID severity; heavy alcohol impairs host defense Cessation; ≤1 drink/day —
Deprescribing immunosuppressive drugs (PPIs, chronic steroids) Remove iatrogenic infection risk; PPIs ↑enteric/respiratory infection; steroids broadly immunosuppress MODERATE (observational + pharmacology) PPIs associated with pneumonia/C. difficile; chronic steroids ↑infection & blunt vaccines Review polypharmacy; use lowest effective steroid dose Do not stop abruptly; clinician-guided
Time-restricted eating / fasting Autophagy, ↓inflammaging, metabolic improvement SPECULATIVE for immunity (mostly animal/metabolic data) Improved metabolic/inflammatory markers; no infection-outcome RCTs in elderly Modest TRE windows if used Risk of undernutrition/sarcopenia/protein deficit in the very old — often net harmful
Cold exposure / sauna Hormesis, heat-shock proteins, possible ↓infection WEAK (small trials; some observational sauna data) Sauna associated with lower respiratory infection/pneumonia risk observationally Regular sauna if tolerated Cardiovascular/orthostatic caution in elderly
B-vitamins (B6/B12/folate), vitamin K2, iron, magnesium, garlic/allicin Cofactors for lymphocyte function; correct deficiency WEAK–MODERATE; benefit in deficient only B6/B12/folate deficiency impairs immunity; garlic small trial ↓colds; magnesium supports vitamin D metabolism Correct to RDA; treat documented deficiency Iron only if deficient (excess ↑infection risk); avoid over-supplementation

Weakest-Support Items

  • Echinacea — Cochrane found no significant preventive benefit; heterogeneous products; positive reviews pooled industry-linked studies.
  • Elderberry — best independent RCT (Macknin 2020) was negative; positive data are small (n=180) and industry-linked.
  • Vitamin A — benefit only in deficient (mainly children in low-income countries); potential harm in the replete.
  • Liposomal glutathione / NAC alone — NAC alone failed in human trials; use the GlyNAC combination if pursued.
  • VDR "activators" (resveratrol, curcumin, quercetin, sulforaphane, berberine) as immune boosters — mechanistic/in-vitro only; no clinical infection outcomes.
  • TRIIM thymic regeneration, metformin (non-diabetic), rapamycin, time-restricted eating — speculative or unproven for immunity in older adults; some carry real risks (rhGH, fasting-induced sarcopenia).
  • Vitamin C for prevention — helps duration (~8%) and severity (~15%) modestly but does not prevent colds in the general population.

Recommendations

  • Do first (highest yield, lowest risk): Ensure full age-appropriate vaccination; establish a resistance + aerobic exercise routine; hit 1.0–1.2 g/kg/day protein; get 7–8 h sleep; stop smoking; moderate alcohol.
  • Test, then treat: Measure 25(OH)D, serum zinc, and (given European-style low intake) selenium; replete deficiencies with daily (not bolus) dosing. Re-check 25(OH)D at ~3 months, aiming ~30–50 ng/mL. Threshold to act: 25(OH)D <20 ng/mL clearly warrants repletion; >50 ng/mL offers no added infection benefit and bolus dosing may carry risk.
  • Reasonable adjuncts: Daily multi-strain probiotic or fermented foods; omega-3 1–2 g/day; optimize oral health; deprescribe unnecessary PPIs/steroids with your clinician.
  • Experimental — only with informed consent/monitoring: Spermidine (6 mg/day) and GlyNAC have suggestive small RCTs and good safety but need confirmation (note the spermidine pilot's overall antibody effect was not statistically significant; benefit appeared confined to low-baseline "non-responders"). TRIIM-style rhGH protocols, rapamycin, and non-diabetic metformin should be regarded as research, not therapy.
  • Benchmarks that would change these recommendations: A completed, adequately-powered RCT of spermidine or GlyNAC with clinical infection endpoints; TAME results (if funded and reported); or new vitamin D infection trials stratified strictly by baseline deficiency and using daily dosing.

Caveats

  • Most micronutrient benefit is a repletion effect; the large replete-population RCTs (VITAL, D-Health) were null for infection and mortality. Do not extrapolate deficiency-correction benefits to already-replete individuals. Vitamin D's ARI benefit in meta-analysis is small (OR 0.92) and confined to daily/weekly — not bolus — dosing.
  • Several "anti-aging" immune therapies rest on tiny or uncontrolled studies (TRIIM n=9; spermidine n=40; GlyNAC single-group) or failed confirmation (RTB101 phase 3 PROTECTOR-1, OR 1.07, p=0.65). Mechanistic plausibility ≠ proven clinical benefit.
  • Observational metformin/pneumonia/COVID associations are heavily confounded (healthy-user and immortal-time biases); the TAME trial that would test causality in non-diabetics remains only partially funded and unreported.
  • Even for vaccines, relative immunogenicity gains do not always translate to reduced hard outcomes: the large 2025 DANFLU-2 pragmatic trial found high-dose flu vaccine did not significantly reduce influenza/pneumonia hospitalization versus standard dose, even though earlier efficacy RCTs favored it.
  • In the very old, aggressive weight loss and fasting can precipitate sarcopenia and undernutrition — potentially net-harmful to immunity.
  • This is an evidence review, not personalized medical advice; supplement and drug decisions should be individualized with attention to renal function, polypharmacy, and existing conditions.

Key sources: VITAL URI analysis [CID 2024]; Jolliffe/Martineau vitamin D ARI meta-analyses [Lancet D&E 2025]; D-Health [Lancet D&E 2022]; ZOE-70 [NEJM 2016]; high-dose flu [NEJM 2014] and [DANFLU-2, NEJM 2025]; zinc in elderly [Prasad, AJCN 2007]; ZENITH [Br J Nutr]; vitamin C [Cochrane 2013] and [severity meta-analysis 2023]; probiotics [Cochrane 2022]; TRIIM [NCT04375657]; GlyNAC [J Gerontol 2023]; spermidine [Aging Cell 2026]; mTOR inhibitors [Lancet Healthy Longevity 2021]; exercise/vaccine [PLOS One 2022]; obesity/immunity [PMC 2024]; selenium [Cambridge, Proc Nutr Soc]; VDR activators [quercetin/VDR, PMC]; echinacea [Cochrane 2014]; elderberry [Hawkins 2019] and [Macknin 2020]; vitamin A [Cochrane 2024]; metformin/TAME [Innov Aging 2018] and [metformin/pneumonia, CID 2023].